Featured Post

Latest Gold News

Economic power could shift further East with Hong Kong gold exchange Russian investment bank sees $1,400 gold by end of 2017 Weak CPI...

Tuesday, November 1, 2011

Biomarin (BMRN) (O) (PEI) (PXP) (BWA) (CADX) Price Targets Changed

Biomarin Pharma (NASDAQ: BMRN), Realty Income Corp. (NYSE: O), Pennsylvania Real Estate Investment Trust (NYSE: PEI), Plains Exploration & Production Company (NYSE: PXP), BorgWarner Inc. (NYSE: BWA) and Cadence Pharmaceuticals, Inc. (NASDAQ: CADX) had price targets on them adjusted by analysts.

Biomarin Pharma (BMRN) had its price target raised by Summer Street Research from $32.00 to $40.00. They have a “Buy” rating on the company.

Realty Income Corp. (NYSE: O) had its price target raised by RBC Capital from $36.00 to $38.00. They have a “Top Pick” rating on the company.

Pennsylvania Real Estate Investment Trust (PEI) had its price target raised by Barclays Capital from $9.00 to $12.00. They have an “Equal Weight” rating on the company.

Plains Exploration & Production Company (PXP) had its price target raised by RBC Capital from $45.00 to $47.00. They have an “Outperform” rating on the company.

BorgWarner Inc. (BWA) had its price target lowered by JPMorgan Chase & Co. (NYSE:JPM) to $89.00.

Cadence Pharmaceuticals, Inc. (CADX) had its price target lowered by Deutsche Bank (NYSE:DB) to $11.00.

No comments: